Molecular Testing for Pulmonary Disease
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity and coverage criteria for molecular and proteomic tests used to assess pulmonary nodules and to aid diagnosis of interstitial lung disease (including IPF) for Blue Cross Blue Shield of North Carolina members and their providers.
No material clinical or coverage changes in this revision.
Coverage Criteria
Nodify XL2 — Covered indications
Covered when ALL of the following are met:
Applies to Nodify XL2 proteomic analysis only.
Nodify XL2 — medically necessary criteria
Nodify XL2 proteomic analysis is considered medically necessary when ALL of the following are met:
Not medically necessary / investigational
Molecular testing/gene expression profiling on bronchial brushings and most other molecular testing of pulmonary specimens is considered not medically necessary for indications other than those explicitly listed:
Evidence summaries
Evidence summaries and clinical validity/utility findings included in the policy document inform coverage considerations for specific molecular tests:
Molecular testing of pulmonary specimens for indications other than those explicitly listed as covered in this policy is not medically necessary. This includes any application of molecular classifiers or gene expression profiling that does not meet the specific coverage criteria described for Nodify XL2.
Clinical guideline panels have not endorsed routine use of gene expression profiling for lung cancer screening or as part of standard diagnostic pathways. For example, the ACCP did not identify studies showing that biomarkers improve the efficiency of lung cancer screening and did not change this position in subsequent updates; ESMO guidelines do not mention GEP for early disease diagnosis; and joint ATS/ERS/JRS/ALAT guidance describes molecular machine-learning approaches for UIP as promising but not yet ready for routine clinical practice pending further validation.
Except where a specific test and its criteria are listed as covered (for example, Nodify XL2 under the conditions specified in this policy), the use of molecular testing for pulmonary disease is considered not medically necessary. Coverage for Nodify XL2 itself is conditional on meeting all stated clinical criteria prior to testing.
Overall, molecular testing of pulmonary specimens remains investigational or not medically necessary for most indications based on current evidence and prior policy determinations. The policy history documents an initial investigational stance and subsequent labeling of these applications as not medically necessary except where explicit coverage criteria are provided.
The American College of Chest Physicians (ACCP) and related guideline panels have noted a lack of evidence that biomarkers improve the efficiency of lung cancer screening. The ACCP specifically reported that no applicable studies comparing molecular biomarkers with established screening criteria were found for inclusion in their systematic review, and guideline authors continue to call for additional research and validation before routine implementation.
Gene expression profiling performed on bronchial brushings (for example, bronchial genomic classifiers such as Percepta) is considered not medically necessary for indications outside of explicitly covered criteria. The policy history documents this technology as previously investigational and currently not covered for general use.
Coding
| 81479 | Unlisted molecular pathology procedure |
| 81554 | Host gene expression classifier for lung nodule risk stratification (Percepta) |
| 0080U | Trackable molecular test (example code listed by policy) |
| 0360U | Trackable molecular test (example code listed by policy) |
| 0406U | Trackable molecular test (example code listed by policy) |
Provider Actions and Requirements
Prior authorization required — Nodify XL2 coverage criteria
Nodify XL2 (plasma proteomic analysis) is covered only when ALL listed clinical criteria are met: pulmonary nodule size 8–30 mm, patient age ≥ 40 years, and pre-test risk of cancer < 50% based on the Solitary Pulmonary Nodule Malignancy Risk Score (Mayo Clinic Model).
- Documentation must show the nodule size, patient age, and Mayo Clinic Model pre-test risk calculation.
- Patient counseling on interpretation of positive and negative results must be documented for coverage.
Submit correct service codes and supporting documentation
The policy lists applicable service codes (81479, 81554, 0080U, 0360U, 0406U); inclusion in the coding list does not guarantee reimbursement and medical records or additional documentation may be requested to determine medical necessity.
- When records are requested, include all information needed to make a medical necessity determination; letters alone are insufficient unless they include required details.
- Inclusion of a code in this section does not guarantee it will be reimbursed; follow payer reimbursement rules on the BCBSNC website.
Billing/coding additions — use updated codes per payer rules
Policy updates added specific CPT/HCPCS codes to the billing/coding section (0080U, 0360U, 0406U, and 81554); providers must bill using current payer rules and the codes listed in the policy.
- Added codes are reflected in the policy history and coding grid; follow BCBSNC billing rules for these codes.
- Inclusion in policy coding does not ensure reimbursement—verify with administrative policies.
Verify member benefits and plan design
Review the member’s Benefit Booklet before ordering or billing for molecular testing—benefit availability and coverage depend on the member’s plan design and benefit language.
- Benefit applicability varies by plan; always verify member benefits prior to testing or submitting claims.
(Reserved)
(No content provided in source to populate this placeholder.)
Step requirement — confirm all clinical criteria before testing
Coverage for Nodify XL2 is conditional on meeting all stated clinical criteria prior to testing; testing performed without meeting these criteria may be denied.
- Ensure documentation demonstrating the nodule is 8–30 mm, patient is ≥40 years, and Mayo Clinic pre-test risk is <50% is in the medical record before ordering the test.
Obtain informed consent prior to testing
Individuals receiving this test should undergo an informed consent discussion comparing benefits and risks of the test versus biopsy prior to testing.
- Document informed consent discussions in the medical record, including alternatives (e.g., biopsy) and interpretation implications.
Include complete medical record documentation when requested
When BCBSNC requests medical records to determine medical necessity, include all specific information needed for the determination; letters of support/explanation alone are not sufficient unless they contain all required information.
- Include nodule size, patient age, Mayo Clinic Model pre-test risk calculation, and documentation of counseling on result interpretation when applicable.
Document patient counseling and eligibility for Nodify XL2
Documentation for coverage must support that the patient was adequately counseled on interpretation of positive and negative Nodify XL2 results and that the clinical eligibility criteria (nodule 8–30 mm, age ≥40, pre-test risk <50% Mayo Model) are met.
- Record counseling content and any shared decision-making notes about how results would influence management.
- Include the Mayo Clinic Model calculation or equivalent documentation of pre-test risk in the chart.
Denial risk — testing outside covered indications
Molecular testing of pulmonary specimens is considered not medically necessary for indications other than the specific Nodify XL2 criteria; ordering tests for other applications risks denial.
- Do not bill molecular testing of pulmonary specimens for indications not specified as covered in the policy.
- If testing outside Nodify XL2 criteria is submitted, expect denial consistent with the policy statement.
Risk of denial if records are incomplete
BCBSNC may request medical records to determine medical necessity; failure to provide required documentation can lead to denial of the claim.
- Provide full clinical information requested (nodule metrics, risk score, counseling documentation) to avoid denials.
- Letters of support are useful but insufficient unless they include all required information.
Historical denial risk for pulmonary specimen molecular tests
Policy history documents that molecular testing/GEP on bronchial brushings and many pulmonary specimen molecular tests were previously considered investigational or not reimbursed, reflecting a historical denial risk for these applications.
- Be aware of the longstanding policy stance that testing outside listed criteria has not been allowed or was investigational in past updates.
Background
Pulmonary nodules are commonly identified incidentally on chest imaging and require assessment of malignancy risk to determine appropriate management. While invasive tissue sampling (biopsy or surgical resection) has been the traditional standard to establish diagnosis, noninvasive and minimally invasive molecular and proteomic tests have been developed to stratify risk and potentially reduce unnecessary procedures. Policy coverage decisions for these tests (for example, Nodify XL2 proteomic analysis) are based on prespecified nodule size, patient age, and pre-test malignancy risk thresholds to identify situations in which the test may meaningfully inform management.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.